Dopascan imaging agent that measures the number of dopamine neurons: Will start a Phase I trial; a Phase II trial is ongoing under a physician-sponsored IND

Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md. Product: Dopascan imaging agent that measures the number of dopamine neurons Indication: Parkinson’s disease Status: Will start a Phase I trial; a ...